Basics Surrounding Oncotarget and Therapy

Most of us know oncotarget as a global, peer-reviewed journal whose popularity has continued to rise. The reviewers primarily focus their endeavors on all cancer types. Lately, oncotarget’s reputation has grown significantly due to their influence. They have been doing several peer-reviews that are not only constructive but also insightful and punctual. Such information helps the researchers a lot in recommending treatment protocols to employ in improving management of cancer patients. At the same time, the journal addresses the effect of managing programs as well as new relaxing agents to enhance the quality of life. As well, the journal extensively explores the proof of new and existing treatments, so as to improve the outcomes with ease. Oncotarget is published by Impact Journals

Some of the Basics Addressed by Cancer Researchers

So far, the first prescription for cancer is chemo and radiotherapies, which most people struggle with. For some severe cancer cases like pancreatic, the forecast happens to be grimmer. According to the information published on Oncotarget, some proteins have been discovered, which could be used for eradication of the duplicating cancer cells. They are still on the ground to ensure that the mechanism they discovered unleashes during mitosis. Should that succeed, it will be suitable for the treatment of aggressive cancer cases that are not instigated by traditional chemo.

According to the specialists, during the mitosis of cancer cells, they discovered a particular mechanism beset by Phenanthridine derivatives that they tested. Either way, they are working towards finding a way through which they catalyze the proliferation of cancer cells. When they are proliferated speedily, they tend to die even faster. Identification of the mechanism and its essence in the treatment of cancer opens an alleyway for the eradication of the rapidly developing tumors, without causing damage to the body tissues.


It is fortunate that health specialists are working behind the scenes to discover effective ways of killing cancer cells. Mikhail is also a renowned specialist with a particular interest in the cancer initiative. He is known for his prowess in research as well as editing the oncotargets. In his endeavors, Mikhail seeks to find permanent solutions for the life-threatening condition. They are a power-packed team ready to pursue their goals to the end.

Learn more:

Omar Boraie Helps Fund Advancement in Precision Medicine for Cancer Treatment

Because of his long-time interest in cancer research, a huge advancement in cancer treatment has been further funded by Omar Boraie, a New Brunswick, New Jersey developer. The $1.5 million pledge Boraie has made will be matched by an anonymous donor. The money goes to the “18 Chair Challenge” whereas Rutgers University’s Cancer Institute supports each of 18 academic disciplines. See,

This particular endowed chair, named the Omar Boraie Chair in Genomic Science, will be headed by Shridar Ganesan, MC, PhD, principal investigator of the precision medicine clinical trial at Rutgers Cancer Institute. Ganesan shoulders many other responsibilities at Rutgers such as associate professor of medicine and pharmacology at Rutgers Robert Wood Johnson Medical School. Robert Wood Johnson Hospital is the flagship hospital for The Cancer institute of New Jersey Network. One of Mr. Boraie’s goals is to make New Brunswick become known as the “Healthcare City.” Precision medicine’s focus, as far as cancer research and treatment is concerned, is the cutting-edge awareness that breaking cancers down into subpopulations through genomic analysis, enables oncologists to treat their patients in a more precise or customized way. This can save time and give hope to those whose cancers are no longer responding to traditional therapies. Other cancer centers are doing research on tumors through gene sequencing as well, but Rutgers got involved early on and have now been applying what they’ve learned to actually treat patients.

In an article published by Newswise Ganesan says “I am honored to be named the Omar Boraie Chair in Genomic Science. This pledge will help innovate clinical research to enable new understandings of cancer biology to benefit patients across even the most challenging disease sites, offering renewed hope for cancer patients and their families.” In a State of the Union Address President Obama echoed the significance of this new research and launched a national Precision Medicine Initiative to help find cures for cancers and other diseases.

The example Mr. Omar Boraie has set will hopefully be repeated by other benefactors. Cancer research has been going on for a long time and this recent discovery that comes out of it is encouraging. Boraie also has a chemistry background, so his interest in cancer research along with his hope that New Brunswick will be named the “Healthcare City” certainly makes his pledge worthwhile for him, for his family and for the hard-working medical professionals in and around Rutgers University.